Targeted Visceral Fat Reduction (Research)
Achieve targeted apoptosis of adipose vasculature using Adipotide (FTPP), combined with complementary fat-targeted and metabolic support peptides. Based on primate data showing ~40% body weight reduction.
Want a personalised protocol?
Our AI generator builds a protocol tailored to your profile and goals.
This protocol is an educational example only. It does not apply to your specific health situation. Medical supervision is required. Peptide therapy is not approved by regulatory bodies for many of the described indications.
Protocol Stack
Adipotide (FTPP)
PrimaryDose
Experimental β not established in humans
Frequency
Daily SC (research protocol)
Timing
Morning, fasted
Duration
4 weeks maximum
AOD-9604
SupportingDose
300 mcg
Frequency
Daily SC
Timing
Morning, fasted (30 min before food)
Duration
4 weeks
5-Amino-1MQ
OptionalDose
50β100 mg
Frequency
Daily oral
Timing
With morning meal
Duration
4 weeks
Monitoring Parameters
- βRenal function panel (creatinine, BUN, eGFR, cystatin C) β every 5 days during active phase
- βElectrolytes (Na, K, Mg, phosphate) β twice weekly
- βBody weight and waist circumference β weekly
- βBlood pressure and heart rate β daily self-monitoring
- βUrinalysis for proteinuria β weekly
- βLipid panel and fasting glucose β baseline and week 4
- βDEXA body composition β baseline and week 8
Expected Outcomes
Week 2: Initial reduction in visceral adiposity detectable on imaging; early weight changes variable
Week 4: End of active phase β anticipated significant reduction in adipose mass in primate-analogous responders
Week 8: Post-cycle assessment; metabolic markers (insulin sensitivity, lipids) expected to improve proportionally
Long-term: Risk of rebound if lifestyle not addressed; caloric restriction and resistance training essential co-interventions
Contraindications
- βTIER 4 β No approved human use. For research/educational purposes only.
- βAny degree of pre-existing renal impairment (absolute contraindication)
- βCardiovascular disease, arrhythmia, or hypertension
- βElectrolyte disorders
- βDiabetes with renal involvement (diabetic nephropathy)
- βPregnancy and breastfeeding
- βConcurrent nephrotoxic medications (NSAIDs, aminoglycosides, contrast agents)
Clinical Notes
Adipotide's mechanism is distinct from all other weight-loss peptides: it does not suppress appetite or modulate incretin pathways, but physically destroys the blood supply to white adipose tissue. AOD-9604 is added as a complementary fat-metabolism peptide (GH fragment 176-191) that stimulates fat breakdown and inhibits lipogenesis via beta-3 adrenergic receptors β mechanistically orthogonal to Adipotide and thus non-redundant. 5-Amino-1MQ inhibits NNMT (nicotinamide N-methyltransferase), an enzyme upregulated in obese adipose tissue that depletes NAD+ β its addition supports mitochondrial metabolic capacity as fat is mobilised. The main clinical risk factor for Adipotide is dose-dependent renal tubular toxicity observed in all primate studies; this makes rigorous renal monitoring non-negotiable.
Case Study
Clinical Practice Example
Male, 44, BMI 47, type 2 diabetes (HbA1c 8.1%), eGFR 88 mL/min/1.73m2 (normal), failed GLP-1 therapy (intolerance), failed bariatric surgery evaluation. Enrolled in hypothetical research protocol with written informed consent and weekly physician oversight. Baseline: weight 138 kg, waist 128 cm, visceral fat area 320 cm2 (CT). After 4-week Adipotide cycle + AOD-9604: weight 121 kg (-17 kg), waist 114 cm, visceral fat area 198 cm2 (-38%). eGFR monitored throughout β nadir 71 mL/min/1.73m2 at week 3, returned to 84 at week 8. HbA1c 6.9% at week 12. Note: This is a hypothetical educational case. The NCT01262664 trial was not completed to publication.